Figure 4From: The antitumor immune response in HER-2 positive, metastatic breast cancer patientsHerceptin in the concentration of 21 μg/ml in the incubation mixture of PBMC (from control healthy people and from breast carcinoma patients) and target cells decreased MDA-MB-361 cell survival (S%), in medium with 10% of autologous serum. E:T ratio was 5:1 (*P < 0.02, **P < 0.004).Back to article page